NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis $3.86 -0.06 (-1.53%) Closing price 08/6/2025 03:50 PM EasternExtended Trading$4.09 +0.23 (+5.93%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock About Titan Pharmaceuticals Stock (NASDAQ:TTNP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Titan Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.80▼$3.9350-Day Range$3.86▼$5.1352-Week Range$3.03▼$14.80Volume5,291 shsAverage Volume45,502 shsMarket Capitalization$3.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. Read More Titan Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreTTNP MarketRank™: Titan Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Titan Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Titan Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Titan Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTitan Pharmaceuticals has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Titan Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.91% of the float of Titan Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTitan Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Titan Pharmaceuticals has recently decreased by 99.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTitan Pharmaceuticals does not currently pay a dividend.Dividend GrowthTitan Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.91% of the float of Titan Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTitan Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Titan Pharmaceuticals has recently decreased by 99.71%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Titan Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Titan Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Titan Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.72% of the stock of Titan Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 31.49% of the stock of Titan Pharmaceuticals is held by institutions.Read more about Titan Pharmaceuticals' insider trading history. Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TTNP Stock News HeadlinesTITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5 at 9:24 PM | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 7 at 2:00 AM | Banyan Hill Publishing (Ad)Titan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | finance.yahoo.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | globenewswire.comSee More Headlines TTNP Stock Analysis - Frequently Asked Questions How have TTNP shares performed this year? Titan Pharmaceuticals' stock was trading at $3.26 at the beginning of 2025. Since then, TTNP shares have increased by 18.4% and is now trading at $3.86. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings results on Wednesday, May, 14th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter. When did Titan Pharmaceuticals' stock split? Titan Pharmaceuticals's stock reverse split before market open on Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings5/14/2025Today8/06/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TTNP CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-145.92% Return on Assets-129.20% Debt Debt-to-Equity RatioN/A Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual Sales$180 thousand Price / Sales19.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book1.45Miscellaneous Outstanding Shares910,000Free Float907,000Market Cap$3.51 million OptionableOptionable Beta1.29 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:TTNP) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.